Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Endocrinol (Buchar) ; -5(1): 52-61, 2019.
Article in English | MEDLINE | ID: mdl-31149060

ABSTRACT

CONTEXT: Cardiomyopathy is the most frequent cardiovascular complication in acromegaly. OBJECTIVE: We aimed to compare some echocardiographic markers in acromegaly patients with controls and find a correlation with disease duration, disease activity, levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). DESIGN: We conducted a cross-sectional case-control study for the period of 2008-2012. SUBJECTS AND METHODS: Acromegaly patients altogether 146 (56 men and 90 women), were divided into four groups according to disease activity and the presence of arterial hypertension (AH). The control group included 83 subjects, matching the patient groups by age, gender and presence of AH. GH was measured by an immunofluorometric method, while IGF-1 by IRMA method. All patients and controls were subjected to one- and two-dimensional transthoracic echocardiography, color and pulse Doppler. RESULTS: We found a thickening of the left ventricular walls and an increase in the left ventricular mass. However, these changes were not statistically significant in all groups and no correlation with disease duration could be demonstrated. As markers of diastolic dysfunction, increased deceleration time and isovolumetric relaxation were registered, which were dependent mainly on age in a binary logistic regression analysis, but not GH or IGF-1. Using absolute values, ejection and shortening fractions were increased in some groups. Using cut-off values, a higher percentage of systolic dysfunction was demonstrated in patients compared to their corresponding controls. Engagement of the right heart ventricle was also found - increased deceleration time and decreased e/a tric ratio. CONCLUSIONS: In conclusion, functional impairments of both ventricles were present, with a predominance of left ventricular diastolic dysfunction.

2.
Exp Clin Endocrinol Diabetes ; 123(1): 66-71, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25611123

ABSTRACT

OBJECTIVE: We described biochemical outcome in regards to different treatment modalities in patients with acromegaly in Bulgaria. PATIENTS AND METHODS: It was a retrospective analysis using data from the Bulgarian Acromegaly Database. Patients with eligible data on at least one treatment modality were included in the study. Disease control was assessed by both GH and IGF-1 values or by GH/IGF-1 alone in cases with one marker. Last follow-up was median 7.0 (range 0.5-51) years after diagnosis. RESULTS: We identified 534 patients with interpretable data, 65.4% of whom were females. Overall surgical cure rate was 28.8%. Adjuvant bromocriptine and cabergoline treatment was analyzed in 133 and 70 patients with disease control achieved in 18.8% and 31.4% respectively. Patients without prior radiotherapy had 16.3% and 18.2% control rates respectively. Predictors of response to dopamine agonist (DA) therapy were disease activity, radiotherapy and medication dose. Adjuvant somatostatin analog (SSA) treatment led to biochemical control in 38.6% of 70 patients. Combination of SSA and cabergoline led to remission in 25% of 20 patients. Growth hormone receptor antagonist (GHRA) alone or in combination resulted in remission in 61.5% of 13 patients. Approximately one third of the patients were cured median 10 years after irradiation. Overall disease control was observed in 51.4% of our patients increasing to 70.3% in the last 5 years of the study period. CONCLUSION: DAs are efficient in less than 20% of non-irradiated patients. They are a good cost-effective alternative for carefully selected patients.


Subject(s)
Acromegaly/therapy , Bromocriptine/administration & dosage , Databases, Factual , Dopamine Agonists/administration & dosage , Adolescent , Adult , Aged , Bulgaria , Cabergoline , Child , Ergolines/administration & dosage , Female , Follow-Up Studies , Humans , Male , Middle Aged , Radiotherapy/methods , Remission Induction , Retrospective Studies , Somatostatin/administration & dosage
3.
Methods Find Exp Clin Pharmacol ; 23(3): 153-6, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11523316

ABSTRACT

The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism. Nine patients with primary aldosteronism (5 with Conn adenoma and 4 with idiopathic hyperaldosteronism) and 9 patients with essential hypertension were included in the study. Systolic and diastolic blood pressure decreased significantly after losartan treatment in both patient groups. Plasma and urinary Kallikrein activity were significantly higher in primary aldosteronism in comparison with essential hypertension. There were no significant changes in the active renin and aldosterone in patients with primary aldosteronism after treatment. Plasma and urinary KA decreased significantly after losartan administration in both groups. Serum VEGF levels in primary aldosteronism were not significantly different from those in essential hypertension and did not change significantly after treatment in either group. In conclusion, losartan, in usual therapeutic doses, lowers blood pressure in patients with primary aldosteronism and essential hypertension. This marked antihypertensive effect in primary aldosteronism could be explained predominantly by blockade of tissue renin-angiotensin system (RAS). The variations in KA could be due to hemodynamic changes. VEGF is not likely to be involved in the action of losartan.


Subject(s)
Angiotensin Receptor Antagonists , Antihypertensive Agents/pharmacology , Hyperaldosteronism/drug therapy , Hypertension/drug therapy , Losartan/pharmacology , Administration, Oral , Age Factors , Aldosterone/analysis , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Endothelial Growth Factors/analysis , Female , Humans , Hyperaldosteronism/metabolism , Hyperaldosteronism/physiopathology , Hypertension/metabolism , Hypertension/physiopathology , Kallikreins/urine , Losartan/administration & dosage , Losartan/therapeutic use , Lymphokines/analysis , Male , Matched-Pair Analysis , Middle Aged , Plasma Kallikrein/analysis , Receptor, Angiotensin, Type 1 , Renin/analysis , Sex Factors , Time Factors , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
4.
Methods Find Exp Clin Pharmacol ; 20(2): 163-8, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9604859

ABSTRACT

Eleven patients with Cushing's syndrome were included in the study. They maintained their usual sodium intake and received a single oral dose of 50 mg of the angiotensin II antagonist receptor losartan for 3 days. Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity. Both systolic and diastolic blood pressure decreased independently of baseline level of active renin. The relationship between kallikrein and renin-angiotensin system are discussed.


Subject(s)
Antihypertensive Agents/therapeutic use , Cushing Syndrome/drug therapy , Kallikreins/analysis , Losartan/therapeutic use , Renin/blood , Administration, Oral , Antihypertensive Agents/administration & dosage , Cushing Syndrome/blood , Cushing Syndrome/complications , Humans , Hypertension/drug therapy , Hypertension/etiology , Kallikrein-Kinin System/drug effects , Losartan/administration & dosage , Renin-Angiotensin System/drug effects
5.
Pain ; 33(2): 173-179, 1988 May.
Article in English | MEDLINE | ID: mdl-2837715

ABSTRACT

Earlier clinical observations of rapid changes of certain neurological dysfunctions after autotraction treatment of patients with lumbar and sacral root affections have been evaluated by objective registration methods. Isokinetic recordings of maximal voluntary strength showed that in 6 out of 8 patients, weakness of the foot dorsal flexor muscles could be more or less completely restored after one session of autotraction resulting in pain relief. In a group of patients with clinical signs of impaired sensibility, the low or abolished SEP responses to nerve stimulation on the affected side were restituted in 4 out of 5 cases during autotraction. The asymmetric leg skin temperatures in 10 patients with sciatic pain levelled off in the 6 cases obtaining pain relief by the traction. The results suggest a causal relationship between pain relief and restitution of certain neurological deficits.


Subject(s)
Evoked Potentials, Somatosensory , Muscles/physiopathology , Pain Management , Skin Temperature , Synaptic Transmission , Traction , Adult , Female , Humans , Intervertebral Disc Displacement/physiopathology , Lumbosacral Region , Male , Middle Aged , Pain/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...